DC-SIGN+DC-SIGNR Antibody (120612) [Phycoerythrin]

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

DC-SIGN (Dendritic Cell-Specific ICAM-3 Grabbing Non-integrin) has been shown to play an important role in regulating Dendritic Cell (DC) and T cell interactions, including antigen presentation to T cells and enhancement of transinfection of CD4+ T cells by HIV-1 (1, 2). Efforts to identify additional type II membrane proteins resulted in the isolation of a molecule related in sequence to DC-SIGN known as DC-SIGNR (DC-SIGN Related) (3, 4). DC-SIGNR shares 73 - 80% amino acid homology with DC-SIGN and is located on human chromosome 19p13.3. Its structure is similar to DC-SIGN and therefore binds mannose residues in a calcium dependent fashion, including ICAM-3 and HIV-1 gp120 (5). DC-SIGNR, also known as L-SIGN (Liver/Lymph node-Specific ICAM-3-Grabbing Non-integrin) and DC‑SIGNR, is polymorphic since allelic variations of the exon 4 encoded sequence have been isolated (5). This is further supported by a study demonstrating the ability to isolate a large repertoire of DC-SIGNR transcripts largely the result of alternative splicing of the 7 coding exons (6). L-SIGN/DC-SIGNR is primarily transcribed in the liver and lymph nodes but not in monocyte derived DC (5). Expression of L-SIGN/DC-SIGNR is restricted to endothelial cells derived from liver sinusoids, lymph node sinuses and capillaries (7) although variable expression in placenta and some monocytic cell lines has also been reported, including both membrane and soluble isoforms of the protein (6). Expression of DC-SIGN is induced during the in vitro generation of DC from either monocytes or bone marrow progenitors, with maximal surface expression at day 7 of culture (1). Immature DC in the skin and mature DC in the tonsil have been demonstrated to express DC‑SIGN (8). Analysis of various tissues and cell lines suggests that DC-SIGN expression is restricted to DC (1) although a more recent report finds evidence of expression in placenta, resting monocytes and monocytic cell lines (6). This discrepancy may be partially related to the multiple isoforms of DC-SIGN transcripts, including both membrane and soluble forms, as well as exon splice variants reported in the latter study (6).

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 1 application: Flow Cytometry.

Showing Publications 1 - 2 of 2.

Publications using FAB1621P	Applications	Species
T Suzuki, Y Sato, K Sano, T Arashiro, H Katano, N Nakajima, M Shimojima, M Kataoka, K Takahashi, Y Wada, S Morikawa, S Fukushi, T Yoshikawa, M Saijo, H Hasegawa Severe fever with thrombocytopenia syndrome virus targets B cells in lethal human infections J. Clin. Invest., 2020-02-03;130(2):799-812. 2020-02-03 [PMID: 31904586] (Flow Cytometry, Human)	Flow Cytometry	Human
Meier R, Franceschini A, Horvath P, Tetard M, Mancini R, von Mering C, Helenius A, Lozach P Genome-wide small interfering RNA screens reveal VAMP3 as a novel host factor required for Uukuniemi virus late penetration. J Virol, 2014-05-21;88(15):8565-78. 2014-05-21 [PMID: 24850728] (Flow Cytometry, Human)	Flow Cytometry	Human

Array FAB1621P

• DC-SIGN+DC-SIGNR Antibodies